MILESTONE: strona spółki
17.08.2020, 18:53
MMD The Update on the Commercial Rollout of CompuFlo® Epidural System in the Second Quarter of 2020
The Board of Directors of Milestone Medical Inc. (WAR: MMD, “the Company”, “the Issuer”) today provided an update on the commercial rollout of CompuFlo® Epidural System in the second quarter ended June 30, 2020.
The Company’s primary focus remains commercialization of the CompuFlo® Epidural System, and the Issuer is moving ahead aggressively towards this goal. Although the Company experienced temporary setbacks due to COVID-19 with hospitals on complete lockdown, The Board of Directors of the Company is pleased to report that the sales and business development pipeline is expanding. The Company in late-stage discussions with a number of premier hospitals in the U.S. Moreover, the CathCheck™ technology has resonated well, given its ability to minimize contact between the patient and provider, which is especially important during the COVID-19 pandemic. Importantly, the CompuFlo® Epidural System is fully validated in terms of safety, efficacy and economics. For these reasons, The Board of Directors of the Company is confident as ever that our technology will become the new standard of care. During the second quarter of 2020 the Company’s parent Milestone Scientific Inc. raised gross proceeds of approximately $19.7 million from the sale of Milestone Scientific's common stock and warrants. The Board of Directors of the Company believes that the financing from its parent provides the Issuer with a substantial runway to help mitigate the risks related to COVID-19, as well as additional resources to accelerate sales and marketing activities around the CompuFlo Epidural System.
The Company’s primary focus remains commercialization of the CompuFlo® Epidural System, and the Issuer is moving ahead aggressively towards this goal. Although the Company experienced temporary setbacks due to COVID-19 with hospitals on complete lockdown, The Board of Directors of the Company is pleased to report that the sales and business development pipeline is expanding. The Company in late-stage discussions with a number of premier hospitals in the U.S. Moreover, the CathCheck™ technology has resonated well, given its ability to minimize contact between the patient and provider, which is especially important during the COVID-19 pandemic. Importantly, the CompuFlo® Epidural System is fully validated in terms of safety, efficacy and economics. For these reasons, The Board of Directors of the Company is confident as ever that our technology will become the new standard of care. During the second quarter of 2020 the Company’s parent Milestone Scientific Inc. raised gross proceeds of approximately $19.7 million from the sale of Milestone Scientific's common stock and warrants. The Board of Directors of the Company believes that the financing from its parent provides the Issuer with a substantial runway to help mitigate the risks related to COVID-19, as well as additional resources to accelerate sales and marketing activities around the CompuFlo Epidural System.